A s one of the world's epicentres for the severe acute respiratory syndrome (SARS) outbreak, the Toronto medical community provided scientific evidence and hands-on experience, making Canadian research key in the battle against SARS (1) . Canadian scientists across the country took responsibility for fighting the disease, and a team of 58 Canadian researchers was first to publish the genome sequence of the human coronavirus believed to cause SARS (2) . This was accomplished using the SARS virus isolated from a patient in Toronto, Ontario and sequenced in Vancouver, British Columbia at the Genome Sciences Centre of the British Columbia Cancer Agency with the help of British Columbia Centre for Disease Control and Health Canada's National Microbiology Laboratory in Winnipeg, Manitoba. Just four years ago the Canadian Institutes of Health Research (CIHR) was created as Canada's premier health research agency with a mandate to create and translate knowledge into improved health for Canadians and a strengthened health care system. In the early days of Canada's SARS outbreak, the CIHR Institute of Infection and Immunity (III) became the testing ground allowing CIHR to rapidly develop the kind of research program that is critical to the understanding and control of new infectious diseases such as SARS. One of the goals of CIHR is to have the capability of responding to the health challenges that affect Canadians with appropriate and timely research programs.
MODELS OF RESEARCH RESPONSE
On April 10, 2003, within days of the World Health Organization's (WHO) global alert on SARS, III took the first step towards launching a long-term CIHR research strategy on emerging infectious diseases. III launched a request for proposals (RFP) for research into the causes and consequences of SARS, creating the early momentum for SARS research in Canada. A teleconference of concerned stakeholders on April 4, 2003 was the starting point for this RFP. The research community in Canada expressed a strong interest in contributing to SARS research. Within two weeks of the call, 18 research teams across Canada had assembled and submitted proposals. Within 10 days, a rapid peer review had been conducted and four applications were approved ( Secondly, delays in securing funding, concerns about the appropriate research questions, the capacity of the research community and delays in the peer review process normally hamper efforts to launch rapid research responses to emerging infectious diseases. However, III took the nontraditional route of committing $250,000 from the institute's operating funds, administered through The University of Western Ontario, to launch the program. Discussions with potential partners revealed a strong interest among provincial government departments, volunteer sector agencies and medical research organizations to join with III to support SARS research. Through partnerships, III was able to increase the total funds available for this RFP to $1.7 million. The funding partners included the Ontario Research and Development Challenge Fund, the Canadian Network for Vaccines and Immunotherapeutics -a Network of Centres of Excellence (NCE), Le Fonds de la recherche en santé du Québec, and Health Canada. Thus, a new model of funding and a mechanism for engaging the research community for public health emergencies was established. Within three weeks of the launch of our RFP, additional funding complemented our efforts. The Michael Smith Foundation for Health Research (MSFHR) received $2.6 million from the government of British Columbia to fund a SARS Accelerated Vaccine Initiative (SAVI). SAVI, headed by Dr Brett Finlay from the University of British Columbia, recruited several laboratories across Canada to undertake a fast-paced vaccine development initiative. This allowed for rapid mobilization of research efforts focused on vaccine development. Two NCEs, namely the Protein Engineering Network of Centres of Excellence (PENCE) and the Mathematics of Information Technology and Complex Systems (MITACS), also committed small amounts of funding for SARS research. The PENCE program was geared to structural and functional studies on SARS viral proteins, and the MITACS effort was focused on mathematical modeling of the SARS outbreak. A great deal has been learned about SARS, but the impact of the disease on the general population beyond the clinical and biomedical concerns clearly justifies the need to continue research at the social and public health levels. Learned. An additional $1.7 million has been committed to this RFA to fund grants over a three-year period (Table 2 ). Development and delivery of this RFA was compressed compared with the standard process, but still required significantly more time than the mechanism used by III and MSFHR. CIHR will continue to refine mechanisms that allow a rapid research response to emerging challenges.
These efforts have been enhanced by the recent announcement by the federal government of the launch of a new Canadian Public Health Agency as recommended late last year by the SARS and Public Health review committee chaired by Dr David Naylor, Dean of Medicine at the University of Toronto. It is expected that this new agency will consider the experience gained by III and MSFHR in its work.
CANADIAN SARS RESEARCH CONSORTIUM
Because research must be backed by investment and collaboration among partners, the Canadian SARS Research Consortium (CSRC) was launched in June 2003. The CSRC concentrates on identifying gaps and coordinating the research effort, and is based on a noncompetitive approach to addressing highly relevant SARS research issues (Table 3) . It functions as a forward-looking body dedicated to maximizing the impact of Canada's resources for SARS research by developing and sustaining a national research agenda and interfacing with the international efforts. Under the umbrella of the CSRC, results of the clinical trial on interferon-alpha therapy of SARS patients have been reported (8) and three potential candidate vaccines have been developed for animal testing (9) . The CSRC is currently developing an inventory of SARS research reagents and patient samples in Canada. The CSRC has mobilized and streamlined the Canadian SARS research effort by bringing together funding partners, eliminating duplication and developing more cooperative interaction between different research groups. The formation of the CSRC provides a preliminary infrastructure which could serve as a model for 
THE FUTURE
The research response to SARS highlights recent provincial and federal investments in health research as contributors to CIHR's ability to quickly develop SARS initiatives to address emerging infectious diseases. SARS has created a demand for research funding around the world. As a federal health research funding agency with a $662 million budget -a fraction of the size of that of the United States National Institutes of Health -we know that our success also depends on the phenomenal commitment, vision, flexibility and support of our partners. The investments made by our partners and by the federal government in building infrastructure such as the Canada Foundation for Innovation, Genome Canada, the Canada Research Chairs program and CIHR itself, have certainly contributed to the initiatives in place to block further tolls in lives, well-being and economical impacts because of SARS, and to learn from the disease to prepare for future infectious diseases. With only extramural programs developed and championed by its 13 institutes, CIHR was created to be responsive to the health needs of Canadians. The III's effort to implement this vision through the development of a creative SARS research agenda is an indicator of the success of the CIHR 'virtual' structure linking researchers across the country, and the CIHR emphasis on partnership, which extends its impact while building collaboration among those who support health research leading to better health and health care in this country. SARS has captured the attention and imagination of the world (7). Yet SARS is still thought to be a 'dry run' for an expected influenza pandemic (5) . The challenge will be to see if the teamwork that has characterized Canada's response to SARS can be sustained for emerging infectious diseases that are not yet in the public arena. This brand of teamwork must also be taken up internationally, as only a cohesive international response will have an impact against newly emerging diseases (6). The tremendous impact of global cooperation, such as that of the WHO's 13-member collaborative multicentre research project on SARS diagnosis, was seen in the swift identification of the coronavirus and its containment. Such international linkages must be strengthened, and the research Lessons learned from SARS (10) . As many of the goals of the CSRC, outlined in Table 3 , have been met (7), we are creating a forward-looking Canadian Rapid Research Team of relevant partners and stakeholders. This will ensure that Canada develops its own capacity and remains an integral part of the international effort to prepare for future research challenges in emerging infectious diseases.
